Ertapenem
Ertapenem is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Complicated intra-abdominal infections
- Community-acquired pneumonia (CAP)
- Complicated urinary tract infections
- Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis
- Elective colorectal surgical prophylaxis
- Acute pelvic infections (postpartum, septic abortion, and post-surgical gynecologic infections)
- Ertapenem is now FDA indicated in pediatrics (3 months-17 yo) for above indications
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Mild-moderate intra-abdominal infections (cholecystitis, cholangitis, diverticulitis, splenic and hepatic abscesses, peritonitis)
- Uncomplicated ESBL infections (e.g. UTIs, billiary tract infections)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Complicated intra-abdominal infections
- Community-acquired pneumonia (CAP)
- Complicated urinary tract infections
- Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis
- Elective colorectal surgical prophylaxis
- Acute pelvic infections (postpartum, septic abortion, and post-surgical gynecologic infections)
- Ertapenem is now FDA indicated in pediatrics (3 months-17 yo) for above indications
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Mild-moderate intra-abdominal infections (cholecystitis, cholangitis, diverticulitis, splenic and hepatic abscesses, peritonitis)
- Uncomplicated ESBL infections (e.g. UTIs, billiary tract infections)
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved